Recital 21, Regulation (EU) 2025/2086

In forcesince 17 Oct 2025

In order to ensure high quality of the dossier for the joint clinical assessment and of the joint clinical assessment report, as well as to ensure the protection of confidential data for commercial reasons, deadlines should be set giving sufficient time to the health technology developer to prepare and submit that dossier and to take the following actions: (a) provide missing information, data, analysis and other evidence as indicated in the Commission’s second request referred to in Article 10(5) of Regulation (EU) 2021/2282; (b) provide further specifications or additional information, data, analyses, or other evidence as provided for in Article 11(2) of Regulation (EU) 2021/2282; (c) provide updates to previously provided information referred to in Articles 10(8) of Regulation (EU) 2021/2282; (d) signal technical or factual inaccuracies in the draft joint clinical assessment and summary reports and any information considered as confidential.